옵션 체인은 다양한 행사가격과 만기일에 대한 Sompo Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Sompo Holdings에 대한 시장 심리를 평가합니다..

Sompo Holdings (OTC:SMPNY) 주식, 옵션 체인

Sompo Holdings was formed in 2010 after the merger of the former Sompo Japan and Nipponkoa Insurance. The name Sompo, which means "nonlife insurance" in Japanese, was adopted as a common brand in 2001 for a planned three-way merger of Yasuda Fire, Nissan Fire, and Taisei Fire. Sompo has around a 26% market share of nonlife insurance premiums in Japan, compared with around 29% and 33% for larger rivals Tokio Marine and MS&AD.

Toyota Photo by RYO Alexandre on Shutterstock

Equities

News

Media

General

DNZOY

KDDIY

MSADY

MUFG

SMFG

SMPNY

TKOMY

미쓰비시 UFJ 파이낸셜 그룹(NYSE:MUFG)과 미쓰이 스미토모 파이낸셜 그룹(NYSE:SMFG)은 토요타 자동차(NYSE:TM)의 전략적 지분 약 1조 3,200억 엔(85억 달러)을 매각할 예정인 것으로 알려졌다. 이러한 대규모 움직임은 일본의 주요 기업들이 광범위한 상호보유 주식 네트워크를 해체하겠다는 강력한 의지를 나타낸다. 이러한 전략적 청산은 ​​토요타의 주가에 대한 부정적인 영향을 완화하기 위해 고안되었다고 블룸버그가 보도했다.

일본 메가 은행들은 $8.5억 달러 규모의 토요타 주식 매각 계획 중: 보도

SOMPO HOLDINGS INC U/ADR by Sompo Hldgs Inc

Sompo Holdings Inc

Private Placement
The private placement is being led by Nantahala Capital and includes investments by Broadfin Holdings and additional healthcare-focused institutional investors. Canaccord Genuity is acting as the sole placement agent for the private placement.
The Company will issue an aggregate of 5,500,000 shares of its common stock at a purchase price of $4.00 per share. The private placement is expected to close on or about May 2, 2025, subject to satisfaction of customary closing conditions. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock issued in the private placement and intends to use the net proceeds from the private placement for working capital and general corporate purposes.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.

Offerings

TLSI

TriSalus Life Sciences Announces $22M Private Placement Of 5.5M Shares Of Common Stock At A Price Of $4/Share

Bragg Gaming Group ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fbrag&amp;,%20esheet=54246441&amp;,%20newsitemid=20250430750544&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+BRAG&amp;,%20index=1&amp;,%20NASDAQ:%3Ca%20class=">BRAG</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fmoney.tmx.com%2Fen%2Fquote%2FBRAG&amp;,%20esheet=54246441&amp;,%20newsitemid=20250430750544&amp;,%20lan=en-US&amp;,%20anchor=TSX%3A+BRAG&amp;,%20index=2&amp;,%20TSX:%3Ca%20class=">BRAG</a>) ("Bragg" or the "Company"), a leading global B2B iGaming content and technology provider, today announced the appointment of Holly Gagnon as Chair of its Board of Directors. Ms. Gagnon, who has served as Lead Director on Bragg's Board of Directors since 2021, succeeds Matevž Mazij in the role. Mr. Mazij will continue to serve as Chief Executive Officer and as a member of the Board of Directors.

Management

BRAG

Bragg Gaming Group Appoints Holly Gagnon As Chair Of The Board Of Directors

<h3>Gainers</h3>
<ul>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock rose 48.2% to $1.26 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock increased by 25.13% to $0.92. The market value of their outstanding shares is at $73.5 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares rose 17.94% to $0.49. The company's market cap stands at $4.9 million. </li>
<li>Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) shares moved upwards by 16.48% to $16.25. The company's market cap stands at $121.2 million. The company's, Q1 earnings came out yesterday. </li>
<li>Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) shares rose 15.62% to $22.5. The market value of their outstanding shares is at $250.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) shares increased by 13.45% to $1.18. The company's market cap stands at $22.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) stock declined by 17.2% to $1.64 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares declined by 12.35% to $0.43. </li>
<li>Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) shares decreased by 8.49% to $77.65. The market value of their outstanding shares is at $88.2 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) stock fell 7.72% to $16.04. The market value of their outstanding shares is at $7.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) stock fell 6.62% to $0.73. The market value of their outstanding shares is at $6.2 million. </li>
<li>Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) shares fell 4.88% to $12.1. The market value of their outstanding shares is at $586.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BALY

CJET

JAKK

JFBR

MULN

NCLH

RCKY

SBUX

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 134.1% to $7.89 during Wednesday's pre-market session. The company's market cap stands at $522.6 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares rose 39.75% to $2.25. The company's market cap stands at $11.1 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock increased by 24.16% to $3.7. The company's market cap stands at $139.3 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 21.47% to $0.02. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 18.72% to $0.2. The market value of their outstanding shares is at $5.2 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) shares moved upwards by 17.44% to $2.76. The company's market cap stands at $216.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock declined by 37.4% to $1.91 during Wednesday's pre-market session. The company's market cap stands at $258.3 million. </li>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares decreased by 28.19% to $84.0. The market value of their outstanding shares is at $2.3 billion. The company's, Q1 earnings came out today. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 21.88% to $1.0. The company's market cap stands at $95.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 18.21% to $0.25. The market value of their outstanding shares is at $3.4 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock declined by 13.03% to $5.21. The company's market cap stands at $117.5 million. </li>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) shares decreased by 12.35% to $8.21. The market value of their outstanding shares is at $564.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARVN

CYCC

GCTK

IMUX

INNV

LGMK

NTHI

PHLT

RGLS

SERA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock rose 23.1% to $5.64 during Wednesday's pre-market session. The company's market cap stands at $15.7 million. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) stock rose 11.84% to $7.08. The market value of their outstanding shares is at $276.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) stock moved upwards by 8.43% to $0.45. The company's market cap stands at $74.8 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) stock increased by 6.23% to $0.58. The company's market cap stands at $29.0 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) stock increased by 6.08% to $0.46. The market value of their outstanding shares is at $14.4 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares moved upwards by 6.08% to $1.31. The company's market cap stands at $158.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock declined by 15.4% to $0.88 during Wednesday's pre-market session. The company's market cap stands at $15.2 million. </li>
<li>Wabash National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) shares decreased by 12.86% to $8.68. The company's market cap stands at $367.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) stock fell 12.38% to $3.61. The company's market cap stands at $153.1 million. </li>
<li>Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) stock fell 9.34% to $25.08. The company's market cap stands at $1.5 billion. The company's, Q1 earnings came out yesterday. </li>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) stock decreased by 8.31% to $0.65. The company's market cap stands at $4.8 million. </li>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock fell 7.56% to $0.24. The market value of their outstanding shares is at $7.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mobile Infrastructure Corporation Common Stock

BEEP

CLIR

CYCU

HTCO

RYDE

STEM

VCIG

WERN

ZBAI

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Nvni Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) shares rose 23.8% to $0.26 during Wednesday's pre-market session. The market value of their outstanding shares is at $24.3 million. </li>
<li>Kingsoft Cloud Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) stock increased by 12.72% to $14.0. The company's market cap stands at $3.7 billion. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares rose 11.99% to $4.56. The company's market cap stands at $57.2 million. </li>
<li>Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) stock moved upwards by 10.87% to $15.9. The company's market cap stands at $4.7 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) stock rose 10.85% to $45.03. The company's market cap stands at $15.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares rose 9.73% to $26.16. The company's market cap stands at $5.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) stock decreased by 17.9% to $4.3 during Wednesday's pre-market session. The company's market cap stands at $120.9 million. </li>
<li>Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares declined by 17.45% to $29.72. The company's market cap stands at $17.7 billion. </li>
<li>Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) stock decreased by 16.57% to $28.1. The market value of their outstanding shares is at $3.3 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares fell 12.6% to $119.95. The company's market cap stands at $12.8 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares fell 10.01% to $259.99. The market value of their outstanding shares is at $87.9 billion. </li>
<li>Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) stock decreased by 6.83% to $24.01. The market value of their outstanding shares is at $663.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EGAN

FRSH

FSLR

HCKT

NVNI

SAGT

SMCI

TENB

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

Ceragon to deliver turnkey industrial connectivity and infrastructure solutions for essential operations
&nbsp;Ceragon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>),&nbsp;a leading solutions provider of end-to-end wireless connectivity,&nbsp;announces that its recently acquired systems integration business, E2E by Ceragon, has closed a $4.1 million agreement with a leading North American oil &amp; gas production company.
Under the agreement, E2E by Ceragon will design, build, and commission a comprehensive operational technology (OT) network infrastructure across more than 100 mission-critical sites. The turnkey solution will use advanced wireless technologies to enable critical security, safety, and operational communications.
Ceragon is expected to deliver this project and recognize revenues within the coming 3 quarters.
The successful execution of this project may open the door to additional opportunities in 2026, including projects at similar or even larger magnitude.
"Our ability to deliver a comprehensive, reliable end-to-end network solution for such critical infrastructure underscores the strategic importance of our recent E2E Technologies acquisition," said Doron Arazi, Ceragon CEO.
This agreement reinforces Ceragon's position as a trusted partner for customers tackling complex, mission-critical challenges, particularly in the private network ecosystem. Looking ahead, Ceragon remains dedicated to driving the future of critical industry networks by combining advanced technologies, integration expertise, and network management capabilities to address the evolving demands of digital transformation.

Contracts

CRNT

Ceragon Enters $4.1M Agreement To Power Mission-Critical Infrastructure For Leading North American Oil & Gas Producer

As Chinese EV giant BYD Co., Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) is gearing up to expand its presence in Europe, satellite images show the company's facility in Hungary taking shape.
What Happened: The images showcase the facility, spread over an area of 1.15 square miles, which can produce over 200,000 units a year, Business Insider <a href="https://www.businessinsider.com/satellite-photos-show-byds-massive-hungary-factory-taking-shape-2025-4">reported</a> on Wednesday.
According to the report, BYD has invested over $4.5 billion in the factory's construction, and the company expects units to start rolling off the line sometime in the latter half of this year.
The company also has plans to set up a facility in Turkey in the near future, and is considering a third factory in Europe, the report suggests.
Why It Matters: The news comes in as BYD has recently <a href="https://www.benzinga.com/25/04/44946809/byd-rejigs-european-strategy-amid-lack-of-market-knowledge-and-modest-dealer-network-report">rejigged its European strategy </a>by hiring executives well-versed with the European market from competitors, and trying to focus on Hybrid products.
BYD has since sold over 37,000 units in the European market in Q1 2025, compared to 8,500 units last year around the same time, that's a 335% YoY increase.
The company has also expressed plans to expand into other territories in Asia, as <a href="https://www.benzinga.com/markets/emerging-markets/25/04/44904375/tesla-rival-byd-targets-japans-minicar-market-with-for-new-affordable-ev">BYD will reportedly enter</a> the Japanese market with an affordable EV priced at around $17,000, putting it squarely against the Japanese minicars.
Elsewhere, BYD also recently revealed its latest <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44630091/teslas-ev-crown-at-risk-as-byd-closes-in-with-breakthrough-charging-tech">battery charging technology</a>, which can provide 250 miles of range on a 5-minute charge.
Price Action: BYDDF currently trades for $48.26, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44945220/chinas-geely-announces-it-will-share-battery-safety-patents-safety-lab-with-the-auto-industry">China's Geely To Share Battery Safety Patents, Unveils World's Largest EV Safety Lab At Shanghai Auto Show</a></li>
</ul>
Photo by Cobalt S-Elino via Shutterstock

Markets

Tech

BYDDF

BYDDY

Tesla Rival BYD's Hungary Facility Takes Shape, Poised To Produce 200,000 EVs Annually: Report

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SMLR

Semler Scientific Acquired 165 Bitcoins Between Apr. 25 And Apr. 29

Vertex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) ("Vertex" or the "Company"), a global provider of indirect tax technology solutions, today announced it has completed a strategic investment in Kintsugi, a San Francisco-based, AI-native startup focused on automating sales tax compliance for small and mid-size businesses (SMBs). Terms of the agreement include a $15 million minority investment representing a 10 percent ownership interest, as well as IP sharing and a commercial arrangement. Additionally, Vertex will join the Kintsugi Board of Directors.
The adoption of tax automation solutions is growing substantially as businesses face increasing compliance complexity associated with eCommerce and SaaS growth, cross-border trade and a patchwork of new tax regulations. Kintsugi automates the entire sales tax compliance lifecycle for small businesses, including tax calculations, filings, and compliance monitoring across multiple jurisdictions. Founded in 2023, Kintsugi has experienced rapid growth and expansion within the U.S., Canada and Europe.

VERX

Vertex Makes $15M Strategic Investment In AI-Driven Startup Kintsugi, Acquiring 10% Stake And Board Seat To Accelerate Automated Sales Tax Compliance For SMBs Through IP Sharing And Commercial Partnership

Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) raises FY2025 Adj EPS guidance from $3.60-$3.90 to $3.63-$3.90 vs $3.76 analyst estimate. Affirms FY2025 sales outlook from $2.02 billion-$2.10 billion to $2.02 billion-$2.10 billion vs $2.05 billion estimate.

Guidance

Federal Signal Raises FY2025 Adj EPS Guidance from $3.60-$3.90 to $3.63-$3.90 vs $3.76 Est; Affirms FY2025 Sales Guidance of $2.02B-$2.10B vs $2.05B Est

WIIM

CLRB

Cellectar Biosciences shares are trading higher after the company announced a plan to explore strategic alternatives.

Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $1.13 by 20.35 percent. This is a 115.87 percent increase over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $2.29 billion which missed the analyst consensus estimate of $2.36 billion by 2.75 percent. This is a 33.64 percent decrease over sales of $3.46 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Western Digital Q3 Adj. EPS $1.36 Beats $1.13 Estimate, Sales $2.29B Miss $2.36B Estimate

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416447-1&amp;h=523693498&amp;u=http%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Positive top-line data for the Phase 2 clinical study in adults with schizophrenia were reported in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416447-1&amp;h=2232133971&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-reports-positive-phase-2-data-nbi-1117568&amp;a=August+2024">August 2024</a>.
"There is a significant need for new and innovative medicines to treat schizophrenia, a disorder that impacts millions of people and their families," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "With positive Phase 2 data in hand, we're excited to advance this investigational novel compound that works directly and selectively at the muscarinic M4 receptor."
The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-1117568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is&nbsp;improvement in the Clinical Global Impression of Severity (CGI-S) scale.
Neurocrine is initiating the Phase 3 study supported by positive top-line data from the Phase 2 clinical study, which met its primary endpoint for the once-daily 20 mg dose. The study found:
<ul>
<li>A clinically meaningful and statistically significant reduction from baseline in the PANSS total score at Week 6 with a placebo-adjusted mean reduction of 7.5 points (p=0.011 and effect size of 0.61) and an 18.2-point reduction from baseline.</li>
<li>A statistically significant improvement across several secondary endpoints, including the CGI-S scale, Marder Factor Score – Positive Symptom Change, and Marder Factor Score – Negative Symptom Change.</li>
<li>NBI-1117568 was generally safe and well tolerated at all doses studied, with minimal gastrointestinal and cardiovascular adverse events.</li>
</ul>
About NBI-1117568 NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development for the treatment of schizophrenia. There are five muscarinic acetylcholine receptors involved in neurotransmission. Muscarinic receptors are central to brain function and validated as drug targets in psychosis and cognitive disorders. As an M4 selective orthosteric agonist, NBI-1117568 offers the potential for a novel mechanism with an improved safety profile without the need for combination therapy to minimize off-target pharmacology-related side effects, while also not being dependent on the presence of acetylcholine for efficacy.
 &nbsp;

Biotech

NBIX

Neurocrine Biosciences Announces Initiation Of Phase 3 Registrational Program for NBI-1117568 As Potential Treatment For Adults With Schizophrenia

Cellectar Biosciences To Explore Strategic Alternatives

Rosenblatt analyst Kevin Cassidy maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Sell and maintains $14 price target.

Price Target

Analyst Ratings

INTC

Rosenblatt Maintains Sell on Intel, Maintains $14 Price Target

CTS Reaffirms FY25 Revenue Outlook Of $520M - $550M Vs. $533.200M Est; Adj EPS Outlook Of $2.2 - $2.35 Vs. $2.11 Est.

<ul>
<li>Approximately 1% domestic same store sales growth, previously low- to mid- single digits;</li>
<li>Global unit growth rate of 16% to 17%, previously 14% to 15%;</li>
<li>SG&amp;A of approximately $140 million, which includes system implementation costs of approximately $4.5 million;</li>
<li>Stock-based compensation expense of approximately $26 million;</li>
<li>Interest expense, net of approximately $40 million, previously approximately $46 million; and</li>
<li>Depreciation and amortization of between $28 and $29 million, previously $29 - $30 million.</li>
</ul>

WING

Wingstop Sees FY25 Same Store Sales Growth ~1%

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) will release earnings results for the first quarter, after the <a href="https://www.benzinga.com/quote/META/earnings">closing bell on Wednesday, April 30.</a>
Analysts expect the Menlo Park, California-based company to report quarterly earnings at $5.22 per share, up from $4.71 per share in the year-ago period. Meta projects to report quarterly revenue at $41.36 billion, compared to $36.45 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The social media and technology company has beaten analyst estimates for revenue in 10 straight quarters.
Meta shares gained 0.9% to close at $554.44 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/META/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Stifel analyst Mark Kelley maintained a Buy rating and cut the price target from $740 to $628 on April 23, 2025. This analyst has an accuracy rate of 83%.</li>
<li>Needham analyst Laura Martin reiterated an Underperform rating on April 23, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and cut the price target from $770 to $700 on April 17, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Cantor Fitzgerald analyst Deepak Mathivanan maintained an Overweight rating and cut the price target from $790 to $624 on April 16, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Wedbush analyst Meta Marshall maintained an Outperform rating and cut the price target from $770 to $680 on April 15, 2025. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="600" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-1024x600.png" alt="" class="wp-image-894197" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-1024x600.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30030037/image-222.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Trading Ideas

Top Wall Street Forecasters Revamp Meta Platforms Expectations Ahead Of Q1 Earnings

Ontrak, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>), a leading value-based behavioral healthcare company powered by proprietary AI and engagement technology, announced it has been re-certified by the National Committee for Quality Assurance (NCQA) as a Credentials Verification Organization (CVO) for the element of license to practice. This re-certification reaffirms Ontrak's ongoing commitment to maintaining the highest standards of quality and compliance across its suite of healthcare solutions, helping health plan customers effectively meet their accreditation goals.
NCQA, a recognized leader in healthcare quality assessment, evaluation, and certification, grants this prestigious re-certification after a voluntary review process and evaluation of a CVO's management of various aspects of its data collection and verification operation, and the process it uses to continuously improve the services it provides.
"This re-certification is more than a compliance milestone, it's a reflection of our unwavering commitment to trust, transparency, and operational excellence." said Brandon LaVerne, Chief Executive Officer and Chief Operating Officer at Ontrak. "At Ontrak health, we anchor our identity around the impact we deliver, and this recognition reinforces the confidence our partners, members, and health plan customers place in us every day."
"Achieving CVO certification from NCQA demonstrates that Ontrak Health has the systems, process and personnel in place to thoroughly and accurately verify providers' credentials and help health plan clients meet their accreditation goals," commented Margaret E. O'Kane, President of the NCQA.

OTRK

Ontrak Announces It Has Been Re-Certified By The National Committee For Quality Assurance As A Credentials Verification Organization For the Element of License To Practice.

Sompo Holdings

Comments

Sompo Holdings

Sompo Holdings (SMPNY) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌